Who is Dr. Brooks, Urologist in Stanford, CA?
Dr. James Brooks, MD is an Urologist, who primarily practices in Stanford, CA with 1 additional practice location. He has been practicing for over 31 years and is board certified. Dr. Brooks completed his residency at Emory Univ Hosp, Psychiatry; Med Coll Of Ga Hosp & Cli, General Surgery. Dr. Brooks is fluent in English, and is currently seeing new patients. Dr. Brooks’s practice accepts Kaiser Permanente, Medicaid, Medicare, Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Brooks’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Brooks?
Dr. James Brooks, MD is a highly-rated, board-certified Urologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Brooks empowers patients to confidently navigate their health journey, specializing in Prostate Cancer, Urologic Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Brooks is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Brooks go to medical school and complete their residency?
Fellowship: Johns Hopkins University MD | Johns Hopkins University,Baltimore, Md, Usa
Residency: Emory Univ Hosp, Psychiatry; Med Coll Of Ga Hosp & Cli, General Surgery | Johns Hopkins Hospital | Johns Hopkins University | Johns Hopkins University Affiliated Hospitals | Johns Hopkins University Affiliated Hospitals
Medical School: Med Coll Of Ga Sch Of Med
Is Dr. Brooks board certified as an Urologist?
Yes, Dr. James Brooks, MD is board certified by the American Board of Urology , American Board of Urology since 2000, American Board of Urology since 2009
What languages does Dr. Brooks speak?
Dr. Brooks and their clinical team can communicate with patients in the following languages:
English
What conditions does an Urologist like Dr. Brooks typically treat?
As an Urologist, Dr. Brooks diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Brooks. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Prostate Cancer
- Prostate Cancer Treatment (PDQ®)
- Prostatic Carcinoma
- Prostate Gland Cancer
- Malignant Prostate Tumor
ICD-10 Codes:
- C61: Malignant neoplasm of prostate
Also known as:
- Elevated PSA Level
- Prostate Cancer Screening
- Prostate Disease
- Prostate-Specific Antigen (PSA) Test
- Prostate Problems
- High Prostate Specific Antigen
- Abnormal PSA Test
- Increased PSA
ICD-10 Codes:
- R9720: Elevated prostate specific antigen [PSA]
Also known as:
- Enlarged Prostate with Urinary Symptoms
- Enlarged Prostate (BPH)
- Enlarged Prostate (Benign Prostatic Hyperplasia)
- BPH with LUTS
- Prostate enlargement with urinary issues
- Benign prostatic hyperplasia with urinary symptoms
ICD-10 Codes:
- N401: Benign prostatic hyperplasia with lower urinary tract symptoms
Also known as:
- Enlarged Prostate
- Enlarged Prostate (BPH)
- Enlarged Prostate (Benign Prostatic Hyperplasia)
- Benign Prostatic Hyperplasia
- BPH
- Prostate Enlargement
ICD-10 Codes:
- N400: Benign prostatic hyperplasia without lower urinary tract symptoms
- N402: Nodular prostate without lower urinary tract symptoms
Also known as:
- History of prostate cancer
- Prostate Cancer
- Prostate Cancer Treatment (PDQ®)
- Past prostate cancer
- Prostate cancer survivor
- Previous prostatic malignancy
ICD-10 Codes:
- Z8546: Personal history of malignant neoplasm of prostate
Also known as:
- Bladder Cancer
- Urinary Bladder Cancer
- Bladder Carcinoma
ICD-10 Codes:
- C679: Malignant neoplasm of bladder, unspecified
Also known as:
- Visible Blood in Urine
- Urine and Urination
- Hematuria (Blood in the Urine)
- Gross hematuria
- Macroscopic hematuria
- Bloody pee
ICD-10 Codes:
- R310: Gross hematuria
What procedures does an Urologist like Dr. Brooks typically perform?
As an Urologist, Dr. Brooks performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Brooks. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Bladder Cancer Medicine Instillation
- Intravesical Chemotherapy
- Bladder Drug Instillation
- Anticancer Bladder Treatment
CPT Codes:
- 51720: Bladder instillation of anticarcinogenic agent (including retention time)
Also known as:
- Bladder and Urethra Scope
- Cystoscopy
- Urethroscopy
- Bladder scope procedure
CPT Codes:
- 52000: Cystourethroscopy (separate procedure)
Also known as:
- Prostate Biopsy
- Needle Biopsy of Prostate
- Punch Biopsy of Prostate
- Prostate Tissue Sample
CPT Codes:
- 55700: Biopsy, prostate; needle or punch, single or multiple, any approach
Does Dr. Brooks accept my insurance?
Dr. Brooks accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Brooks accept in Stanford, CA?
Dr. Brooks in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Medicaid
Medicare
OptumRx Administered Payer
Other Provider Networks
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Brooks' office located?
Recognitions
Awards
Stanford University
Keith and Jan Hurlbut Professor
Best Doctors Inc.
Listing in Guide to America's Top Surgeons, Consumers' Research Counc
Stanford University School of Medicine
Leutje-Stubbs Faculty Scholar
Kidney Cancer Association
Eugene P. Schonfeld Medical Research Award
Doris Duke Foundation
Clinician Scientist Award
Dornier Research Scholar, American Foundation for Urologic Disease
Publications
tionwide prevalence of lymph node metastases in Gleason score 3?+?3?=?6 prostate cancer.
, 2014
Prostate cancer risk profiles of asian-american men
, 2014
Utilization of rel mass biopsy in patients with rel cell carcinoma.
, 2014
Epigenetic changes in histologically normal prostate tissues.
, 2013
Comprehensive gene expression changes associated with mouse posttal kidney development.
, 2013
Uriry TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort
, 2013
Treatment and mortality in men with localized prostate cancer
, 2013
Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and Cycli2.
A Model for the Design
, 2013
Maging localized prostate cancer in the era of prostate-specific antigen screening.
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Higher rates of upgrading and upstaging
Differential D methylation with age displays both common
, 2013
mR-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression
, 2012
Evaluation of Putative Rel Cell Carcinoma Markers PAX-2, PAX-8
, 2012
Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice
, 2012
Methods for registration of magnetic resonce images of ex vivo prostate specimens with histology
, 2012
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer
, 2012
Translatiol genomics: The challenge of developing cancer biomarkers
, 2012
PIVOT and the challenges of localized prostate cancer care
The Potential Impact of Reproducibility of Gleason Grading
, 2011
D methylation profiling reveals novel biomarkers
, 2011
Integrated genomic alyses of ovarian carcinoma
, 2011
Small Prostate Size and High Grade Disease-Biology or Artifact?
, 2011
Comparison of prostate cancer tumor volume
, 2011
Specificity of brachyury in the distinction of chordoma from clear cell rel cell carcinoma
, 2011
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence
The distribution of PAX-2 immunoreactivity in the prostate gland, semil vesicle
, 2010
Cary Prostate Active Surveillance Study
, 2010
Molecular Stratification of Clear Cell Rel Cell Carcinoma by Consensus Clustering
, 2010
Gene expression changes induced by genistein in the prostate cancer cell line LNCaP
, 2010
Adjuvant docetaxel and abbreviated androgen deprivation therapy
, 2010
Prognostic significance of prostate cancer origiting from the transition zone
, 2009
Disorders of sex development expose transcriptiol autonomy of genetic sex and androgen
, 2009
Alteration of Gene Expression Sigtures of Cortical Differentiation
, 2009
Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen
, 2009
Recommendations for the Reporting of Surgically Resected Specimens of Rel Cell Carcinoma
, 2009
Inhibition of prostaglandin synthesis and actions by genistein
, 2009
Recommendations for the reporting of surgically resected specimens of rel cell carcinoma The
, 2009
STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
, 2009
CD 9 and vimentin distinguish clear cell from chromophobe rel cell carcinoma.
, 2009
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
, 2008
Identification of candidate prostate cancer genes through comparative expression-profiling of semil
, 2008
Postoperative prostate
, 2008
hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen
, 2008
The impact of tumor volume on outcomes after radical prostatectomy
, 2008
Genomic profiling reveals altertive genetic pathways of prostate tumorigenesis
, 2007
Placental S100 (S100P) and GATA3
, 2007
Endothelin-1 promotes cell survival in rel cell carcinoma through the ETA receptor
, 2007
Selenomethionine induced transcriptiol programs in human prostate cancer cells
, 2007
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues
, 2007
Cell-line and tissue-specific sigtures of androgen receptor-coregulator transcription
, 2006
Application of genomic technologies to human prostate cancer
, 2006
Gene expression profiling predicts survival in conventiol rel cell carcinoma
, 2006
Preoperative PSA velocity is an independent prognostic factor
, 2005
Genome-wide characterization of gene expression variations
, 2005
Juvenile posttraumatic high-flow priapism: current magement dilemmas
, 2005
A transcriptiol profile of aging in the human kidney
, 2004
Molecular activity of 1
, 2004
Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?
, 2004
Lower body mass index is associated with a higher prostate cancer detection rate
, 2004
Alysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cD
, 2004
Time trends in pathologic features of radical prostatectomy - impact of family history
, 2004
Gene expression in the normal adult human kidney assessed by complementary D microarray
, 2004
Diverse effects of methylseleninic acid on the transcriptiol program of human prostate cancer cells
, 2004
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
, 2004
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
, 2003
Gene expression patterns in rel cell carcinoma assessed by complementary D microarray
, 2003
Expression of FKBP12 in benign
, 2003
Microarray alysis in prostate cancer research.
, 2002
Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells
, 2002
Atomy of the rectourethralis muscle
, 2002
Transcriptiol programs activated by exposure of human prostate cancer cells to androgen
Nationwide prevalence of lymph node metastases in Gleason score 3?+?3?=?6 prostate cancer.
, 2014
Prostate cancer risk profiles of asian-american men
, 2014
Reply.
, 2014
Utilization of renal mass biopsy in patients with renal cell carcinoma.
, 2014
Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP
Evaluation of SF-1 Expression in Testicular Germ Cell Tumors
, 2013
Epigenetic changes in histologically normal prostate tissues.
, 2013
Comprehensive gene expression changes associated with mouse postnatal kidney development.
, 2013
Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort
, 2013
Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1
, 2013
Treatment and mortality in men with localized prostate cancer
, 2013
Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and CyclinA2.
A Model for the Design
, 2013
Managing localized prostate cancer in the era of prostate-specific antigen screening.
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Higher rates of upgrading and upstaging
Differential DNA methylation with age displays both common
, 2013
mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene
, 2012
Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8
, 2012
Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice
, 2012
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
, 2012
Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology
, 2012
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer
, 2012
Performance Characteristics of Prostate
, 2012
Deficiency in Mammalian Histone H2B Ubiquitin Ligase Bre1 (Rnf20
, 2012
LONG-TERM OUTCOMES FROM A PROSPECTIVE TRIAL OF STEREOTACTIC BODY RADIOTHERAPY FOR LOW
, 2012
Translational genomics: The challenge of developing cancer biomarkers
, 2012
PIVOT and the challenges of localized prostate cancer care
The Potential Impact of Reproducibility of Gleason Grading
, 2011
DNA methylation profiling reveals novel biomarkers
, 2011
Integrated genomic analyses of ovarian carcinoma
, 2011
Small Prostate Size and High Grade Disease-Biology or Artifact?
, 2011
A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer
, 2011
Comparison of prostate cancer tumor volume
, 2011
Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma
, 2011
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence
Smoking and adverse outcomes at radical prostatectomy.
The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle
, 2010
Canary Prostate Active Surveillance Study
, 2010
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals
, 2010
Gene expression changes induced by genistein in the prostate cancer cell line LNCaP
, 2010
Adjuvant docetaxel and abbreviated androgen deprivation therapy
, 2010
Prognostic significance of prostate cancer originating from the transition zone
, 2009
Disorders of sex development expose transcriptional autonomy of genetic sex and androgen
, 2009
Alteration of Gene Expression Signatures of Cortical Differentiation
, 2009
Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen
, 2009
Prostatic Soy Isoflavone Concentrations Exceed Serum Levels After Dietary Supplementation
, 2009
Recommendations for the Reporting of Surgically Resected Specimens of Renal Cell Carcinoma
, 2009
Inhibition of prostaglandin synthesis and actions by genistein
, 2009
Recommendations for the reporting of surgically resected specimens of renal cell carcinoma The
, 2009
STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
, 2009
Temporal Changes in Gene Expression Induced by Sulforaphane in Human Prostate Cancer Cells
, 2009
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.
, 2009
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
, 2008
Identification of candidate prostate cancer genes through comparative expression
, 2008
Postoperative prostate
, 2008
hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen
, 2008
The impact of tumor volume on outcomes after radical prostatectomy
, 2008
Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts
, 2007
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis
, 2007
Placental S100 (S100P) and GATA3
, 2007
A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells
, 2007
A variant TMPRSS2 isoform
, 2007
Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor
, 2007
Selenomethionine induced transcriptional programs in human prostate cancer cells
, 2007
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues
, 2007
Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription
, 2006
Application of genomic technologies to human prostate cancer
, 2006
Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
, 2006
Refractory hematuria from amyloidosis successfully treated by splenectomy
, 2006
Modest induction of phase 2 enzyme activity in the F-344 rat prostate
, 2006
Gene expression profiling predicts survival in conventional renal cell carcinoma
, 2006
The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer
, 2005
Preoperative PSA velocity is an independent prognostic factor
, 2005
Genome-wide characterization of gene expression variations
, 2005
Juvenile posttraumatic high-flow priapism: current management dilemmas
, 2005
Reg IV: A promising marker of hormone refractory metastatic prostate cancer
, 2005
Resveratrol-induced gene expression profiles in human prostate cancer cells
, 2005
Molecular targets of Doxazosin in human prostatic stromal cells
, 2005
Positive family history of prostate cancer not
, 2005
Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.
, 2005
A transcriptional profile of aging in the human kidney
, 2004
Vascular invasion predicts recurrence after radical prostatectomy
, 2004
Molecular activity of 1
, 2004
Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?
, 2004
Lower body mass index is associated with a higher prostate cancer detection rate
, 2004
Analysis of vitamin D
, 2004
Time trends in pathologic features of radical prostatectomy - impact of family history
, 2004
Biochemical remission after resection of prostate cancer lung metastasis
, 2004
Gene expression in the normal adult human kidney assessed by complementary DNA microarray
, 2004
Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer
, 2004
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
, 2004
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
, 2003
Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray
, 2003
Biochemical recurrence without PSA progression characterizes a subset of patients after radical
, 2003
Differential gene-expression patterns in genital fibroblasts of normal males and 46
, 2003
Expression of FKBP12 in benign
, 2003
Identification of potential prostate cancer preventive agents through induction of quinone reduct
, 2002
Polymorphisms in the androgen receptor and type II 5 alpha
, 2002
Microarray analysis in prostate cancer research.
, 2002
Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells
, 2002
Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells
, 2002
Anatomy of the rectourethralis muscle
, 2002
Transcriptional programs activated by exposure of human prostate cancer cells to androgen
What is Dr. Brooks's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Brooks's National Provider Identifier (NPI) number is 1043320005.
What common questions do patients ask about Dr. Brooks?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Brooks
What is Dr. James Brooks's specialty?
Dr. Brooks is a Urologist near Stanford, CA.
What does an Urologist do?
A urologist is a healthcare professional with specialization in managing both benign and malignant medical and surgical disorders of the genitourinary system and adrenal glands. They possess extensive knowledge and skills in endoscopic, percutaneous, and open surgical techniques for addressing congenital and acquired conditions of the urinary and reproductive systems, as well as their associated structures.
Is this Dr. James Brooks affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Brooks is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see an Urologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see an Urologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is James Brooks accepting new patients in Stanford, CA?
Yes, Dr. James Brooks is accepting new patients at this time.
Does Dr. James Brooks offer online booking?
Please contact Dr. Brooks's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with James Brooks?
Please contact Dr. Brooks's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. James Brooks have?
Dr. James Brooks is certified by the American Board of Urology.
Other Urologist Near Stanford, CA
Urologist
Accepting patientsUrologist
Accepting patientsUrologist
Accepting patients